Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

Rhea-AI Summary

Tourmaline Bio (NASDAQ: TRML) has announced its plans to present two posters at the 19th Annual Cardiometabolic Health Congress (CMHC) in Boston, MA, from October 17-19, 2024. The presentations highlight the company's commitment to understanding inflammatory cardiovascular risk and potential therapeutic mechanisms of IL-6 inhibition.

The first poster, titled 'Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention', involves collaborations with Atropos Health and Wake Forest University School of Medicine. The second poster, 'Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis', is a joint effort with Wake Forest University School of Medicine and an independent researcher from Toronto.

These presentations underscore Tourmaline Bio's focus on developing transformative medicines for patients with life-altering immune and inflammatory diseases.

Positive

• Tourmaline Bio will present two posters at a major industry conference, demonstrating ongoing research efforts
• The company is collaborating with respected institutions like Wake Forest University School of Medicine, potentially enhancing research credibility

Negative

• None.

News Market Reaction – TRML

-8.48%

-8.48% Session move

In the trading session that priced this news, TRML declined 8.48%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it expects to present two posters at the upcoming 19th Annual Cardiometabolic Health Congress (CMHC), taking place October 17-19, 2024, in Boston, MA.

These posters highlight Tourmaline's ongoing commitment to further characterizing inflammatory cardiovascular risk, as well as potential therapeutic mechanisms of IL-6 inhibition.

Poster Presentations:
Title: Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention
Authors: Emil deGoma, MD¹; Yung Chyung, MD¹; John Walsh, MD¹; C. William Pike, MD²; Jananee Muralidharan, MD²; Vincent Marino²; J. Craig Davis²; Saurabh Gombar, MD, PhD²; Michael D. Shapiro, DO, MCR³
Affiliations:
¹Tourmaline Bio, Inc., New York, NY, USA
²Atropos Health, Inc., New York, NY, USA
³Wake Forest University School of Medicine, Winston-Salem, NC, USA

Title: Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis
Authors: Saeid Mirzai, DO¹; Emil deGoma, MD²; John Walsh, MD²; Raya Mahbuba, MSc³; Yung Chyung, MD²; Michael D. Shapiro, DO, MCR¹
Affiliations:
¹Wake Forest University School of Medicine, Winston-Salem, NC, USA
²Tourmaline Bio, Inc., New York, NY, USA
³Independent researcher, Toronto, ON, Canada

For more information, please visit https://www.cardiometabolichealth.org/19th-annual-cmhc/.

About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).

About Pacibekitug
Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing pacibekitug in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration.

For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com.

Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com  

Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com  

FAQ

What is Tourmaline Bio (TRML) presenting at the 2024 Cardiometabolic Health Congress?

Tourmaline Bio (TRML) is presenting two posters at the 2024 Cardiometabolic Health Congress: one on the utilization of high-sensitivity C-reactive protein testing in ASCVD prevention, and another on the effect of IL-6 inhibition on Lipoprotein(a) levels.

When and where is the 2024 Cardiometabolic Health Congress that Tourmaline Bio (TRML) is attending?

The 19th Annual Cardiometabolic Health Congress (CMHC) that Tourmaline Bio (TRML) is attending is taking place from October 17-19, 2024, in Boston, MA.

What areas of research do Tourmaline Bio's (TRML) poster presentations focus on?

Tourmaline Bio's (TRML) poster presentations focus on characterizing inflammatory cardiovascular risk and potential therapeutic mechanisms of IL-6 inhibition.

Who are Tourmaline Bio's (TRML) collaborators for the poster presentations at the 2024 CMHC?

Tourmaline Bio (TRML) is collaborating with Atropos Health, Wake Forest University School of Medicine, and an independent researcher from Toronto for the poster presentations at the 2024 CMHC.